An-Li Yu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
An-Li Yu has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
- Cheng-Hsuan Tsai
Division of Cardiology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
3 shared publications Chi-Chao Chao
3 shared publicationsMao-Yuan Su
3 shared publicationsHui-Chun Huang
2 shared publicationsJimmy Jyh-Ming Juang
2 shared publications- Li-Ting Ho
Division of Cardiovascular Center, Department of Internal Medicine National Taiwan University Hospital Taipei Taiwan
2 shared publications
Latest Publications
- Open Access
- 3 November 2026
- Published by Elsevier in JACC: Asia
- Vol. 6 (11) , 2726-2737
Prevalence of Transthyretin Amyloidosis Among Older Taiwanese Patients With Heart Failure With Preserved Ejection Fraction
- 3 November 2026
- Published by Elsevier in JACC: Asia
- Vol. 6 (11) , 2726-2737
Open AccessPrevalence of Transthyretin Amyloidosis Among Older Taiwanese Patients With Heart Failure With Preserved Ejection Fraction
- Open Access
- 25 February 2025
- Published by Elsevier in Journal of the Formosan Medical Association
- Vol. 125 (5) , 544-549
Left atrial reservoir strain as a surrogate marker for atrial fibrillation burden in patients with non-valvular atrial fibrillation
- 25 February 2025
- Published by Elsevier in Journal of the Formosan Medical Association
- Vol. 125 (5) , 544-549
Open AccessLeft atrial reservoir strain as a surrogate marker for atrial fibrillation burden in patients with non-valvular atrial fibrillation
- Open Access
- 19 December 2024
- Published by Elsevier in JACC: Advances
- Vol. 4 (2) , 101511
Effect of Tafamidis on Clinical and Functional Parameters in Transthyretin Amyloid Cardiomyopathy
- 19 December 2024
- Published by Elsevier in JACC: Advances
- Vol. 4 (2) , 101511
Open AccessEffect of Tafamidis on Clinical and Functional Parameters in Transthyretin Amyloid Cardiomyopathy
- Open Access
- 16 January 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (2) , e030512
Use of Technetium‐99m‐Pyrophosphate Single‐Photon Emission Computed Tomography/Computed Tomography in Monitoring Therapeutic Changes of Eplontersen in Patients With Hereditary Transthyretin Amyloid Cardiomyopathy
Background: Hereditary transthyretin amyloid cardiomyopathy (hATTR‐CM) is a progressive and fatal disease. Recent evidence indicates that bone scintigraphy may serve as a tool to monitor the effectiveness of hATTR‐CM treatment. The objective of this study was to examine how eplontersen therapy influences the semiquantitative uptake of technetium‐99m‐pyrophosphate in individuals diagnosed with hATTR‐CM. Methods and Results: We retrospectively analyzed a prospective cohort from the NEURO‐TTRansform trial, including patients with hATTR‐CM receiving eplontersen (45 mg/4 weeks). A control group comprised patients with hATTR‐CM who had not received eplontersen, inotersen, tafamidis, or patisiran. Technetium‐99m‐pyrophosphate single‐photon emission computed tomography/computed tomography was conducted at baseline and during follow‐up. Thirteen patients with hATTR‐CM were enrolled, with 6 receiving eplontersen and 7 serving as the control group. The median follow‐up time was 544 days. The eplontersen group exhibited a significant decrease in volumetric heart and lung ratio (3.774 to 2.979, P =0.028), whereas the control group showed no significant change (4.079 to 3.915, P =0.237). Patients receiving eplontersen demonstrated a significantly greater reduction in volumetric heart and lung ratio compared with the control group (−20.7% versus −3.4%, P =0.007). Conclusions: The volumetric heart and lung ratio used to quantify technetium‐99m‐pyrophosphate uptake showed a significant reduction subsequent to eplontersen treatment in individuals diagnosed with hATTR‐CM. These findings suggest the potential efficacy of eplontersen in treating hATTR‐CM and highlight the value of technetium‐99m‐pyrophosphate single‐photon emission computed tomography/computed tomography as a tool for monitoring therapeutic effectiveness.
- 16 January 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (2) , e030512
Open AccessUse of Technetium‐99m‐Pyrophosphate Single‐Photon Emission Computed Tomography/Computed Tomography in Monitoring Therapeutic Changes of Eplontersen in Patients With Hereditary Transthyretin Amyloid Cardiomyopathy
Background: Hereditary transthyretin amyloid cardiomyopathy (hATTR‐CM) is a progressive and fatal disease. Recent evidence indicates that bone scintigraphy may serve as a tool to monitor the effectiveness of hATTR‐CM treatment. The objective of this study was to examine how eplontersen therapy influences the semiquantitative uptake of technetium‐99m‐pyrophosphate in individuals diagnosed with hATTR‐CM. Methods and Results: We retrospectively analyzed a prospective cohort from the NEURO‐TTRansform trial, including patients with hATTR‐CM receiving eplontersen (45 mg/4 weeks). A control group comprised patients with hATTR‐CM who had not received eplontersen, inotersen, tafamidis, or patisiran. Technetium‐99m‐pyrophosphate single‐photon emission computed tomography/computed tomography was conducted at baseline and during follow‐up. Thirteen patients with hATTR‐CM were enrolled, with 6 receiving eplontersen and 7 serving as the control group. The median follow‐up time was 544 days. The eplontersen group exhibited a significant decrease in volumetric heart and lung ratio (3.774 to 2.979, P =0.028), whereas the control group showed no significant change (4.079 to 3.915, P =0.237). Patients receiving eplontersen demonstrated a significantly greater reduction in volumetric heart and lung ratio compared with the control group (−20.7% versus −3.4%, P =0.007). Conclusions: The volumetric heart and lung ratio used to quantify technetium‐99m‐pyrophosphate uptake showed a significant reduction subsequent to eplontersen treatment in individuals diagnosed with hATTR‐CM. These findings suggest the potential efficacy of eplontersen in treating hATTR‐CM and highlight the value of technetium‐99m‐pyrophosphate single‐photon emission computed tomography/computed tomography as a tool for monitoring therapeutic effectiveness.
- 8 February 2023
- Published by Elsevier in JACC: Cardiovascular Imaging
- Vol. 16 (6) , 866-867
Tafamidis Treatment Decreases 99mTc-Pyrophosphate Uptake in Patients With Hereditary Ala97Ser Transthyretin Amyloid Cardiomyopathy
- 8 February 2023
- Published by Elsevier in JACC: Cardiovascular Imaging
- Vol. 16 (6) , 866-867
Tafamidis Treatment Decreases 99mTc-Pyrophosphate Uptake in Patients With Hereditary Ala97Ser Transthyretin Amyloid Cardiomyopathy